Unknown

Dataset Information

0

Inflation of tumor mutation burden by tumor-only sequencing in under-represented groups.


ABSTRACT: With the recent FDA approval of tumor mutational burden-high (TMB-H) status as a biomarker for treatment with a PD-1 inhibitor regardless of tumor type, accurate assessment of patient-specific TMB is more critical now more than ever. Using paired tumor and germline exome sequencing data from 701 patients newly diagnosed with multiple myeloma, including 575 self-reported White patients and 126 self-reported Black patients, we observed that compared to the gold standard of filtering germline variants with patient-paired germline sequencing data, TMB estimates were significantly higher in both Black and White patients when using public databases for filtering non-somatic mutations; however, TMB was more significantly inflated in Black patients compared to White patients. TMB as a biomarker for patient selection to receive immune checkpoint inhibitors (ICIs) therapy without patient-paired germline sequencing may introduce racial bias due to the under-representation of minority groups in public databases.

SUBMITTER: Asmann YW 

PROVIDER: S-EPMC7979755 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC3463230 | biostudies-literature
| S-EPMC8456145 | biostudies-literature
| S-EPMC7378265 | biostudies-literature
| S-EPMC4699643 | biostudies-literature
| S-EPMC8506044 | biostudies-literature
| S-EPMC5651797 | biostudies-literature
| S-EPMC7082297 | biostudies-literature
| S-EPMC8404326 | biostudies-literature
| S-EPMC6945555 | biostudies-literature
| S-EPMC8328823 | biostudies-literature